In the past week, BMRN stock has gone up by 4.96%, with a monthly gain of 6.60% and a quarterly plunge of -3.31%. The volatility ratio for the week is 2.37%, and the volatility levels for the last 30 days are 2.72% for Biomarin Pharmaceutical Inc. The simple moving average for the last 20 days is 5.38% for BMRN stock, with a simple moving average of -4.68% for the last 200 days.

Is It Worth Investing in Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) Right Now?

Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) has a price-to-earnings ratio that is above its average at 114.61x. and a 36-month beta value of 0.38. Opinions on the stock are mixed, with 16 analysts rating it as a “buy,” 3 as “overweight,” 10 as “hold,” and 0 as “sell.”

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


The average price predicted for Biomarin Pharmaceutical Inc. (BMRN) by analysts is $110.29, which is $22.76 above the current market price. The public float for BMRN is 184.84M, and at present, short sellers hold a 1.78% of that float. On November 21, 2023, the average trading volume of BMRN was 1.48M shares.

BMRN) stock’s latest price update

Biomarin Pharmaceutical Inc. (NASDAQ: BMRN)’s stock price has plunge by 0.01relation to previous closing price of 87.52. Nevertheless, the company has seen a 4.96% surge in its stock price over the last five trading sessions. InvestorPlace reported 2023-11-09 that In the fluctuating U.S. stock market, biotech stocks have faced challenges. The sector’s most popular index, iShares Biotechnology ETF (NASDAQ: IBB ), is dropping 9% year to date (YTD).

Analysts’ Opinion of BMRN

Many brokerage firms have already submitted their reports for BMRN stocks, with Wells Fargo repeating the rating for BMRN by listing it as a “Overweight.” The predicted price for BMRN in the upcoming period, according to Wells Fargo is $100 based on the research report published on November 15, 2023 of the current year 2023.

BMRN Trading at 2.10% from the 50-Day Moving Average

After a stumble in the market that brought BMRN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.68% of loss for the given period.

Volatility was left at 2.72%, however, over the last 30 days, the volatility rate increased by 2.37%, as shares surge +5.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.66% lower at present.

During the last 5 trading sessions, BMRN rose by +4.96%, which changed the moving average for the period of 200-days by -21.99% in comparison to the 20-day moving average, which settled at $83.30. In addition, Biomarin Pharmaceutical Inc. saw -15.42% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at BMRN starting from Ajer Jeffrey Robert, who sale 5,000 shares at the price of $90.00 back on Aug 16. After this action, Ajer Jeffrey Robert now owns 60,804 shares of Biomarin Pharmaceutical Inc., valued at $450,000 using the latest closing price.

FUCHS HENRY J, the President, Worldwide R&D of Biomarin Pharmaceutical Inc., sale 12,000 shares at $90.43 during a trade that took place back on Aug 10, which means that FUCHS HENRY J is holding 176,187 shares at $1,085,111 based on the most recent closing price.

Stock Fundamentals for BMRN

Current profitability levels for the company are sitting at:

The net margin for Biomarin Pharmaceutical Inc. stands at +6.91. The total capital return value is set at 0.18, while invested capital returns managed to touch 2.55. Equity return is now at value 3.11, with 2.26 for asset returns.

Based on Biomarin Pharmaceutical Inc. (BMRN), the company’s capital structure generated 24.33 points at debt to equity in total, while total debt to capital is 19.57. Total debt to assets is 17.57, with long-term debt to equity ratio resting at 24.10. Finally, the long-term debt to capital ratio is 19.39.

When we switch over and look at the enterprise to sales, we see a ratio of 7.13, with the company’s debt to enterprise value settled at 0.06. The receivables turnover for the company is 4.91 and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.67.


To sum up, Biomarin Pharmaceutical Inc. (BMRN) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.